Predicting short term response to anti-inflammatory therapy in young children with asthma

Stefan Zielen1, Martin Christmann, Magdalena Kloska

  • 1Allergologie, Pneumologie und Mukoviszidose, Klinikum der Johann Wolfgang-Goethe-Universität, 60590 Frankfurt, Germany.

Insights

Predicting asthma treatment response in children is possible using lung function tests. Pre-bronchodilatory Forced Expiratory Volume in one second (FEV1) and airway reversibility effectively indicate short-term response to inhaled corticosteroids (ICS) and montelukast.

Area of Science:

  • Pediatric Pulmonology
  • Asthma Management
  • Biomarker Discovery

Background:

  • Current anti-inflammatory asthma treatments for young children include inhaled corticosteroids (ICS) and montelukast (LTRA).
  • Identifying predictors of treatment response is crucial for optimizing pediatric asthma care.

Purpose of the Study:

  • To identify biomarkers that predict short-term (6-week) response to ICS and LTRAs in children with asthma.
  • To evaluate the efficacy of pre-bronchodilatory FEV1 and airway reversibility as predictive markers.

Main Methods:

  • 102 children (4-7 years) with episodic asthma were enrolled.
  • 45 symptomatic children were randomized to receive either montelukast or fluticasone for 6 weeks.
  • Biomarkers including FEV1, airway reversibility, methacholine challenge, eNO, allergy status, IgE levels, and eosinophils were assessed.

Main Results:

  • Both montelukast and fluticasone showed equal effectiveness in improving FEV1 (p = 0.44).
  • Pre-bronchodilatory FEV1 (p < 0.001) and airway reversibility (p = 0.04) at randomization strongly correlated with favorable treatment response.
  • Other tested biomarkers, including exhaled nitric oxide and IgE levels, were not predictive.

Conclusions:

  • Pre-bronchodilatory FEV1 and airway reversibility are promising indicators for predicting short-term anti-inflammatory therapy response in young children with asthma.
  • These lung function parameters may aid in tailoring asthma treatment strategies for pediatric patients.
Abstract

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: